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Methods: Urine samples were obtained in 354 consecutive
patients, referred to the department of rheumatology for one of
the following diseases [Osteoarthritis (OA), rheumatoid arthritis
(RA), ankylosing spondylitis (AS), undetermined inflammatory
arthritis (UIA), osteoporosis (OP)] and in 66 controls (CTRL).
CTX I and II were assayed using a competitive ELISA method.
CTX I and II correlations were studied by linear regression.
Differences in CTX levels between groups were studied with
analysis of variance, taking into account age, sex and BMI.
Results: Cross sectional study. 144 males and 276 females;
mean (SD) age 59(17); mean CTX I 228.9 (204) ng/mL; mean
CTX II 375.7(408.6) ng/mL.
CTX I was significantly higher in females than in males (p=0.006).
There was a correlation between CTX I and CTX II concentra-
tions (R=0.34, p<0.001). CTX I but not CTX II was correlated
with age (p=0.001 and p=0.46 respectively).
CTX I was significantly higher in OP than in CTRL (p=0.02).
However there was no significant difference of CTX I levels
between OP and OA, RA, SA and UIA. CTX I levels were not
statistically different between CTRL and the various articular
diseases.
CTX II concentrations were higher in all the articular diseases
than in CTRL (OA/CTRL p=0.05; RA/CTRL p=0.02; AS/CTRL
p=0.004, UIA/CTRL p=0.02) but no difference was found between
OP and CTRL (p=0.3).
Lastly CTX II levels were not significantly different between OA,
RA, SA and UIA. (all p> 0.2).
Conclusions: Both CTX I and II were increased in muscoskeletal
diseases. Compared to CTRL, CTX I levels were signifcantly
increased only in patients with OP.
By contrast CTX II were significantly increased in OA, inflamma-
tory rheumatisms but also OP. Surprisingly CTX II was as high
in OP as in inflammatory diseases and in OA. The influence of
the treatments on CTX levels remains to be investigated.
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CHONDROITIN SULPHATE IN BLOOD CIRCULATION
AND PURITY TESTING IN SUPPLEMENTS AND DRUGS
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N.K. Karamanos1
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France
Purpose: Structure analysis of serum chondroitin sulfate (CS)
is very important as information could be received in respect to
structural alterations of serum CS in several pathological condi-
tions along with its pharmacological profile. Due to the low blood
concentration of CS and a general lack of adequate analytical
methodology that ensures high recovery of CS and sensitive
determination, the factors influencing its structure and concen-
tration have not yet been fully identified. Furthermore, the safety
and purity of CS preparations from various sources should be
addressed since they are widely used as nutritional supplements
and drugs.The aim of this study was therefore to develop: 1) a
high sensitive assay that can be used for identification and deter-
mination of hyaluronan (HA) contamination in CS commercially
available preparations and 2) a serum pretreatment procedure
and an accurate analytical methodology for the determination of
total CS and its disaccharide composition in serum.
Methods: A reversed polarity capillary electrophoresis (CE) ap-
proach has been developed for purity analysis of CS preparations
from various tissues as well as for monitoring the variously sul-
phated CS disaccharides in blood circulation. Charge density
distribution of CS preparations and purity testing for identification
of HA was performed by direct CE analysis of aqueous CS solu-
tions. For analysis of serum samples, they were treated with pro-
tease and CS chains were completely recovered by precipitation.
CS were selective degraded to variously sulphated disaccharides
following enzymic digestion of with chondro/dermato-lyases.
Results: Direct analysis of aqueous CS solutions from various
tissues ensured the complete separation and identification of CS
and HA. Selective enzymic digestion of various CS preparations
with chondroitinases and analysis under the same CE condi-
tions, ensures the complete separation between the sulphated
CS-disaccharides and HA within 15 min. Analysis as low as
50 μg of CS preparations can be used to identify even 0.3%
HA contamination. For analysis of serum samples CS chains
were completely recovered by precipitation. Following enzymic
treatments and CE analysis, the composition of disaccharides in
serum was found to be rich in 4-sulphated and non-sulphated
CS-derived disaccharides.
Conclusions: The developed methodological approach is sensi-
tive and accurate and can be easily used for the identification of
HA contamination in commercially available preparations of CS,
the charge homogeneity of CS as well as for the determination of
the CS concentration and sulphation profile in blood serum. The
approach will be useful for pharmacokinetic studies and disease
monitoring.
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Purpose: Pentosidine (PEN), a major member of advanced
glycation end-products, belongs to promising molecules that el-
evated concentrations in body fluids and tissues could indicate
deleterious changes caused by specific post-translational modi-
fication in metabolism of long-lived proteins, lipids, and carbohy-
drates. Quantification of PEN in body fluids or tissues by means
of sensitive HPLC methods helps to monitor the pathological
modifications of proteins in a number of diseases.
In this study, we determined PEN in patients with diabetes mel-
litus (DM) and rheumatic diseases. For that, highly sensitive
and reproducible HPLC method combined with sensitive fluores-
cent detection was developed. Then we determined PEN levels
in biological samples from laboratory mice (C57/6 black) with
spontaneously induced arthritis. To analyze reduced formation of
PEN in vivo, we tested antioxidative and antirheumatic effects of
vitamin C and Boswellin supplementation of these mice.
Methods: For PEN determination we established sensitive
method based on reversed phase gradient HPLC combined
with fluorescence detection (λexc./λem. = 335/385 nm). The con-
ditions are as follows: compact glass column CGC Separon SGX
C18, 150x3 mm; mobile phase consisted of 0.02 M heptaflu-
orobutyric acid, 0.01M ammonium sulphate and linear gradient
is given by variable concentration of acetonitrile (12.5 - 25%),
column temperature: 40°C; flow rate: 0.5 ml/min; time of HPLC
run: 30 minutes. The method was applied to hydrolyzed and pu-
rified body fluid samples from patients with osteoarthritis (OA),
rheumatoid arthritis (RA), diabetics of type 1 (DM1) and type 2
(DM2), healthy controls as well as to samples from serum and
experimental mice tissue extracts.
Results: In blood samples of patients with RA and DM2, the ac-
cumulation of PEN was doubled compared with healthy controls.
In case of OA patients, mild elevation of PEN was also observed.
We found significant correlation of PEN concentrations between
studied body fluids. The association of PEN concentrations with
the age of studied subjects was observed.
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Conclusions: These results indicate that pentosidine may play
an important role in the process of pathophysiology of chronic
rheumatic diseases and DM complications.
Supported by the Ministry of Health of the Czech Republic (grant
No. NR/7895-3 and research project No. 00023728).
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Purpose: Bone undergoes reformation in response to the de-
mands placed upon it. Examination of both the serum and
synovial fluid BAP concentrations in joint disease may be valu-
able in determining the different local and systemic effects that
occur to bone in response to exercise and injury. BAP has been
shown to be a good biomarker for early osteoblastic activity
when joint injury is present. The investigators have performed
previous studies demonstrating the capability of the commercially
developed Metra® BAP ELISA to determine differences in bio-
logical activity of equine serum and synovial fluid (SF) samples.
BAP is well conserved across species, and the Quidel Corpo-
ration has demonstrated species cross reactivity with the horse.
Thus, because the horse is a good translational model of OA for
biomarker evaluation, the objective of this study was to validate
the use of equine serum and SF with the Metra® BAP ELISA.
Fig. 1. Specificity was examined for serum (A) and SF (B) by mixing together the high, medium and low quality control samples (mQC). This mixture was serially
diluted at 1:2, 1:4, 1:8, and 1:10. The results of this serial dilution were then compared to the standard curve that was derived using the standards provided by the
manufacturer by comparing the absorbance to the concentration. The samples demonstrated parallelism to the master standard curve.
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Fig. 2. Linearity of dilution was analyzed in serum (A) and SF (B) by serially diluting QC samples (high, medium, and low) at the following dilutions: 1:2, 1:4, 1:8, and
1:10. The concentration of each dilution was determined from the standard curve and the observed concentration was plotted against the reciprocal of the dilution
(1/dilution).
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Methods: Metra® BAP ELISAs (Quidel Corporation) were used
for this validation study according to manufacturer protocols.
Internal quality control (QC) samples were prepared using the
highest concentration standard provided by the manufacturer
(140 U/L). To create QC samples, fresh serum was collected
from 3 normal horses and fresh SF was collected aseptically
from 12 middle carpal and 12 radiocarpal joints from 6 normal
horses. The samples were respectively pooled together for fur-
ther processing and analysis. Each group of pooled samples
were spiked with a known amount of standard to create samples
with high, medium and low levels of BAP. The QC samples were
used to determine the precision, specificity, sensitivity, accuracy,
linearity of dilution, and stability of this assay with equine serum
and SF.
Results: The standard optical density (OD) values exhibited ac-
ceptable reproducibility of the standard curve over 10 plates with
an overall inter-assay precision mean coefficient of variation (CV)
of 8.1% (range; 4.9-12.3%). Serum and SF samples exhibited ac-
ceptable intra-assay and inter-assay precision over 3 plates with
an overall mean CV of 3.3% (range; 0.1-8.1%) and 7.2% (range;
5.7-9.6%), respectively for the serum, and 2.6% (range; 0.2-
7.5%) and 7.1% (range; 4.8-8.8%), respectively for the SF. Paral-
lelism of serum and SF sample dilutions (1:2, 1:4, 1:8, and 1:10)
was demonstrated when compared to the standard curve (Fig. 1).
Lowest detection limit of the assay was determined to be 1.6
U/L. Percent recovery for serum was 103.1% for high, 111.6%
for medium, and 116.1% for low QC samples. Percent recovery
for SF was 64.8% for high, 86.1% for medium, and 91.2% for low
QC samples. Linearity of serum and SF sample dilutions (1:2,
1:4, 1:8, and 1:10), was demonstrated (Fig. 2). The results also
demonstrated that no more than 2 freeze/thaw cycles should be
